71719-06-7

Basic information

• Product Name: 3-BROMO-5-(2-PYRROLIDINYL)PYRIDINE
• Synonyms: 5-BROMO-3-(2-PYRROLIDINYL)PYRIDINE;3-BROMO-5-(2-PYRROLIDINYL)PYRIDINE;3-BROMO-5-PYRROLIDIN-2-YL-PYRIDINE;(S)-3-bromo-5-(pyrrolidin-2-yl)pyridine hydrochloride;(R,S)-3-BroMo Nornicotine
• CAS NO: 71719-06-7
• Molecular Formula: C₉H₁₁BrN₂
• Molecular Weight: 227.1
• EINECS: 200-258-5
• Product Categories: Heterocycles;Nicotine Derivatives;Aromatics;Chiral Reagents;Mutagenesis Research Chemicals
• Mol File: 71719-06-7.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 295.4°C at 760 mmHg
• Flash Point: 132.5°C
• Appearance: /
• Density: 1.434g/cm³
• Vapor Pressure: 0.00153mmHg at 25°C
• Refractive Index: 1.57
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.56±0.10(Predicted)
• CAS DataBase Reference: 3-BROMO-5-(2-PYRROLIDINYL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-(2-PYRROLIDINYL)PYRIDINE(71719-06-7)
• EPA Substance Registry System: 3-BROMO-5-(2-PYRROLIDINYL)PYRIDINE(71719-06-7)

Safety Data

• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 71719-06-7(Hazardous Substances Data)

Usage

Description

3-Bromo-5-(2-pyrrolidinyl)pyridine is a chemical compound that is an analog of Nornicotine (N757000). It is characterized by the presence of a bromine atom at the 3-position and a pyrrolidinyl group at the 5-position on a pyridine ring. This unique structure makes it a valuable compound for various applications.

Uses

Used in Immunoassays:
3-Bromo-5-(2-pyrrolidinyl)pyridine is used as haptens in immunoassays for the detection of specific antibodies. Its structural similarity to Nornicotine allows it to bind to antibodies that target this compound, enabling the development of sensitive and specific immunoassays for various applications.
Used in Pharmaceutical Research:
As a Nornicotine analog, 3-Bromo-5-(2-pyrrolidinyl)pyridine can be used in pharmaceutical research to study the effects of Nornicotine and develop potential therapeutic agents targeting the nicotine receptors. This can lead to the discovery of new drugs for the treatment of nicotine addiction and related disorders.
Used in Chemical Synthesis:
3-Bromo-5-(2-pyrrolidinyl)pyridine can also be used as a starting material or intermediate in the synthesis of various chemical compounds. Its unique structure allows for further functionalization and modification, making it a versatile building block for the development of new molecules with potential applications in various industries.

InChI:InChI=1/C9H11BrN2/c10-8-4-7(5-11-6-8)9-2-1-3-12-9/h4-6,9,12H,1-3H2

Upstream product

• 64319-85-3 3-bromo-5-(4,5-dihydro-3H-pyrrol-2-yl)-pyridine 
• 201610-91-5 5-bromo-3-(2-pyrrolin-1-yl)pyridine 
• 201292-62-8 3-(5-Bromo-pyridine-3-carbonyl)-1-vinyl-pyrrolidin-2-one 
• 20986-40-7 ethyl 5-bromo-3-pyridinecarboxylate 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 

Downstream Products

• 71719-09-0 5-bromo-3-(1-methyl-2-pyrrolidinyl)pyridine 
• 7076-23-5 (+)-nornicotine 

Relevant articles and documents

Prescreening of Nicotine Hapten Linkers in Vitro To Select Hapten-Conjugate Vaccine Candidates for Pharmacokinetic Evaluation in Vivo

Since the demonstration of nicotine vaccines as a possible therapeutic intervention for the effects of tobacco smoke, extensive effort has been made to enhance nicotine specific immunity. Linker modifications of nicotine haptens have been a focal point for improving the immunogenicity of nicotine, in which the evaluation of these modifications usually relies on in vivo animal models, such as mice, rats or nonhuman primates. Here, we present two in vitro screening strategies to estimate and predict the immunogenic potential of our newly designed nicotine haptens. One utilizes a competition enzyme-linked immunoabsorbent assay (ELISA) to profile the interactions of nicotine haptens or hapten-protein conjugates with nicotine specific antibodies, both polyclonal and monoclonal. Another relies on computational modeling of the interactions between haptens and amino acid residues near the conjugation site of the carrier protein to infer linker-carrier protein conjugation effect on antinicotine antibody response. Using these two in vitro methods, we ranked the haptens with different linkers for their potential as viable vaccine candidates. The ELISA-based hapten ranking was in an agreement with the results obtained by in vivo nicotine pharmacokinetic analysis. A correlation was found between the average binding affinity (IC50) of the haptens to an anti-Nic monoclonal antibody and the average brain nicotine concentration in the immunized mice. The computational modeling of hapten and carrier protein interactions helps exclude conjugates with strong linker-carrier conjugation effects and low in vivo efficacy. The simplicity of these in vitro screening strategies should facilitate the selection and development of more effective nicotine conjugate vaccines. In addition, these data highlight a previously under-appreciated contribution of linkers and hapten-protein conjugations to conjugate vaccine immunogenicity by virtue of their inclusion in the epitope that binds and activates B cells.

COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES

The invention is in general directed to compounds, such as tannic acid, nicotine, nicotine derivatives and pyrrolidine derivatives of nicotine, and methods for diagnosing, preventing or alleviating the symptoms of amyloid-associated diseases, for example, neuronal diseases, such as, for example, Alzheimer's disease, compounds and methods for inhibiting ion channel activity of beta amyloid, and methods of diagnostic imaging of A/3 fibrils.

MODULATORS OF ACETYLCHOLINE RECEPTORS

The present invention provides a class of pyridine compounds which are modulators of acetylcholine receptors, i.e., compounds which displace acetylcholine receptor ligands from their binding sites. Invention compounds may act as agonists, partial agonists